FIXX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• In April 2025, we announced dosing of the first patient in Part B of the SIGNAL-AA Phase 2a clinical trial. The Part B portion of SIGNAL-AA is an open-label clinical trial that enrolled 33 patients with severe or very severe AA (baseline Severity of Alopecia Tool (“SALT”) scores of 50-100), with a m…

• Efficacy is evaluated on the basis of mean percentage change from baseline in SALT scores as well as the proportion of subjects achieving various relative and absolute SALT score improvements at week 36, with off-drug follow-up through week 52. The trial is intended to support advancement into pivot…

• We announced completion of enrollment in the SIGNAL-AA Part B clinical trial in October 2025. In May 2026, we announced that the first patient had been dosed in the OLE portion of Part B.

• In July 2026, we announced 36-week topline results from the SIGNAL-AA Part B trial. The prespecified primary efficacy analysis was evaluated on the basis of mean percentage change from baseline in SALT scores in the modified intent-to-treat (“mITT”) population at Week 36. Additional prespecified 36-…

• Key topline efficacy results from Part B of SIGNAL-AA at Week 36 include:

相对上期删除的文字 · 来源:10-Q · 2026-05-05

• In April 2025, we announced dosing of the first patients in Part B of the SIGNAL-AA Phase 2a clinical trial. The Part B portion of SIGNAL-AA is an open-label clinical trial dosing severe or very severe AA patients with a maximum duration of current episode of four years. Patients will be treated wit…

• We announced completion of enrollment in the SIGNAL-AA Part B clinical trial in October 2025. We enrolled 33 patients in the SIGNAL-AA Part B trial and dosing remains ongoing. We expect to report 36-week topline data from the SIGNAL-AA Part B trial in mid-2026.

• Following completion of the SIGNAL-AA Part B trial through 52 weeks, eligible patients can enter an open-label extension (“OLE”) period to enable longer-term follow-up and continued dosing. The first patient has been dosed in the OLE portion of Part B.

• In April 2025, we announced the initiation of an OLE trial for eligible patients that completed Part A to enable longer-term follow-up of patients. The OLE trial is complete, and we intend to report findings from the trial with the Part B 36-week topline results in mid-2026.

• In April 2025, we announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track designation (“FTD”) to bempikibart for the treatment of AA. FTD is a process designed to facilitate the development and expedite the review of new drugs to treat serious diseases and fill an unm…

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings.

• Any preliminary or topline data should be viewed with caution until the final data is available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change…

• We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, the U.S. Foreign Corrup…

• designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In…

• Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and

相对上期删除的文字 · 来源:10-Q · 2026-05-05

• We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of

• Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct…

• Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed…

• We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited, and they must be acceptable to the FDA or approved by foreign regulatory authorities. Suppliers and manufacturers, including us, must meet applicable manufacturing requi…

• other reasons, we may be forced to increase the manufacturing of the materials ourselves, for which we currently have limited capabilities and resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. Any interruption of the develo…